论文部分内容阅读
目的研究吉西他滨联合铂类二线治疗晚期非小细胞肺癌患者的近期疗效及安全性。方法回顾性分析2009年3月至2011年5月福建省肿瘤医院内科收治的使用吉西他滨联合铂类二线治疗晚期非小细胞肺癌患者47例,给予吉西他滨联合铂类化疗,吉西他滨用量为1.0 g/(m2.次),第1、8天给药,所有患者均有可测量和评价病灶,至少治疗2周期,有完整近期疗效及不良反应评价资料。结果 47例均可评价疗效。总共化疗周期数129个,中位数2周期,按RECIST标准评价疗效,完全缓解0例,部分缓解10例(21.3%),稳定25例(53.2%),进展12例(25.5%),疾病控制率达74.5%。主要不良反应为骨髓抑制和胃肠道反应。结论吉西他滨联合铂类二线治疗晚期非小细胞肺癌疗效肯定,不良反应可以耐受。若能结合检测肿瘤基因表达情况,则有助于对二线治疗的临床选择更加合理化和个体化。
Objective To study the short-term efficacy and safety of gemcitabine and platinum on second-line treatment of advanced non-small cell lung cancer. Methods Forty-seven patients with advanced non-small cell lung cancer treated with gemcitabine combined with platinum in the Department of Internal Medicine of Fujian Provincial Tumor Hospital from March 2009 to May 2011 were retrospectively analyzed. Gemcitabine combined with platinum-based chemotherapy was given in an amount of 1.0 g / m2), administered on the first and eighth days, all patients were measurable and evaluated lesions, at least 2 cycles of treatment, a complete short-term efficacy and adverse reaction evaluation data. Results 47 cases can evaluate the curative effect. The total number of chemotherapy cycles was 129 and the median was 2 cycles. According to the RECIST standard, 0 cases were completely relieved, 10 cases were partially relieved (21.3%), 25 cases were stable (53.2%), 12 cases were advanced (25.5%), Control rate of 74.5%. The main adverse reactions were myelosuppression and gastrointestinal reactions. Conclusion Gemcitabine combined with platinum second-line treatment of advanced non-small cell lung cancer is effective, adverse reactions can be tolerated. Combining with the detection of tumor gene expression can help to rationalize and individualize clinical options for second-line treatment.